Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: formatherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/13/2022 | $46.00 → $21.00 | Overweight | Cantor Fitzgerald |
| 11/12/2021 | $54.00 → $40.00 | Outperform | SVB Leerink |
| 8/17/2021 | $55.00 → $53.00 | Buy | HC Wainwright & Co. |
| 8/2/2021 | $58.00 | Buy | Craig Hallum |
The "Believe it!" Campaign Will be Featured on TV Networks and Radio Stations Across the U.S., Driving Viewers to SCDBelieveIT.org The Sickle Cell Disease Association of America, Inc. (SCDAA), in partnership with Forma Therapeutics, Inc. (NASDAQ:FMTX) today announced that they have joined forces to create a public service announcement (PSA) to drive awareness and advance meaningful understanding of sickle cell disease (SCD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005106/en/ SCD occurs in one in every 365 Black Americans and affects an estimated 100,000 individuals in the U.S. 1 alone, according to the Centers for D
Novo Nordisk and Forma Therapeutics, Holdings Inc. (NASDAQ:FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005393/en/ The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk's strategy t
Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia Highlighted progress across portfolio at inaugural Research and Development (R&D) Day Appointed new members of Executive Team to prepare for growth in late-stage clinical development and commercialization Cash balance of $395.9 million positions company with runway through the third quarter of 2024
Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the treatment of relapsed or refractory acute myeloid leukemiaFDA has accepted Forma's NDA for olutasidenib, with a PDUFA target action date of February 15, 2023Forma to receive an upfront payment of $2.0 million and is eligible to receive an additional $17.5 million upon the achievement of certain near-term regulatory, approval, and first commercial sale milestones, as well as potential future development and commercial milestone payments of $215.5 million and tiered royalties in the low-teens to mid-thirtiesIf approved, olutasidenib would be Ri
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, today announced that it will release second quarter 2022 financial results Friday, August 5, 2022. Forma management will host an investment community conference call at 8 a.m. Eastern Daylight Time (EDT) on August 5, 2022 to discuss these financial results and provide a business update. Investors may participate in the call by using the registration link here. Once registered, participants will receive a dial-in number as well as a PIN to enter the event. A live webcast of the conference call will
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that its Board of Directors granted to Agustín Melián, M.D. and Linea Aspesi non-qualified stock options of 118,000 and 59,000 shares, respectively, of its common stock pursuant to Inducement Non-Qualified Stock Option Agreements (the "Stock Options") and 79,000 and 39,000 restricted stock units, respectively, pursuant to Inducement Restricted Stock Unit Agreements (the "RSUs," and together with the Stock Options, the "Inducement Grants"). On June 30, 2022, Forma announced the appointment
Agustín Melián, M.D. to be named Executive Vice President, Head of Research and Development and Linea Aspesi to be named Senior Vice President, Chief Human Resources Officer Appointments position Forma for the next phase of growth in late-stage global development and commercialization Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer, and other rare hematologic diseases and cancers, today announced the appointment of Agustín Melián, M.D. to EVP, head of research and development and Linea Aspesi to SVP, chief human resources officer. Both executives will join Forma effective July 11, 2022. "As the co
Updated results from the completed Phase 1 study of etavopivat in patients with sickle cell disease (SCD) Study design for the Phase 2 Gladiolus Study of etavopivat in patients with transfusion-dependent (TD) SCD or non-TD/TD thalassemia Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced its participation in the European Hematology Association (EHA) 2022 Hybrid Congress, taking place June 9-17, the Foundation for Sickle Cell Disease Research (FSCDR) Sickle Cell Disease Research and Educational Symposium and Sickle Cell Disease Scientif
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will participate in the Jefferies Healthcare Conference taking place June 8-10, 2022. Forma will present on June 9, 2022 at 2:00 p.m. Eastern Daylight Time (EDT). A webcast of the conference presentation will be available in the "News & Investors" section of Forma's website at www.FormaTherapeutics.com. About Forma Therapeutics Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to tran
Expanding etavopivat development in 2022 with Phase II trial exploring transfusion burden across sickle cell disease (SCD), thalassemia and myelodysplastic syndromes (MDS) Phase 1 trial of FT-7051 in mCRPC proceeding with predicted efficacious dose range under evaluation and exploring alternative dosing schedule FT-3171 (USP1 inhibitor) introduced targeting BRCA mutant tumors with investigational new drug (IND) filing expected in the first half of 2023 Early stage research pipeline focusing on red blood cell (RBC) health and novel mechanisms in rare hematology and targeted oncology indications Forma well-positioned with $441 million in cash to progress programs in rare hematologic
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
SC 13G/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13D/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13D/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13G - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13G/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13G/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13G/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13G/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13G - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13G/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
Cantor Fitzgerald resumed coverage of Forma Therapeutics with a rating of Overweight and set a new price target of $21.00 from $46.00 previously
SVB Leerink reiterated coverage of Forma Therapeutics Hldgs with a rating of Outperform and set a new price target of $40.00 from $54.00 previously
HC Wainwright & Co. reiterated coverage of Forma Therapeutics Hldgs with a rating of Buy and set a new price target of $53.00 from $55.00 previously
Craig Hallum initiated coverage of Forma Therapeutics with a rating of Buy and set a new price target of $58.00
SVB Leerink reiterated coverage of Forma Therapeutics Hldgs with a rating of Outperform and set a new price target of $54.00 from $65.00 previously
H.C. Wainwright reiterated coverage of Forma Therapeutics with a rating of Buy and set a new price target of $55.00 from $53.00 previously
Oppenheimer initiated coverage of Forma Therapeutics with a rating of Outperform and set a new price target of $60.00
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that its Board of Directors granted to Agustín Melián, M.D. and Linea Aspesi non-qualified stock options of 118,000 and 59,000 shares, respectively, of its common stock pursuant to Inducement Non-Qualified Stock Option Agreements (the "Stock Options") and 79,000 and 39,000 restricted stock units, respectively, pursuant to Inducement Restricted Stock Unit Agreements (the "RSUs," and together with the Stock Options, the "Inducement Grants"). On June 30, 2022, Forma announced the appointment
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of Ifeyinwa (Ify) Osunkwo, MD, MPH, to the executive leadership team as the company's inaugural chief patient officer and senior vice president. In this role, Dr. Osunkwo will be responsible for realizing Forma's vision to transform the lives of patients by improving access and care through partnerships with global patient and community stakeholders. She will join Forma in the first quarter of 2022. "This appointment of a chief patient officer boldly represents our commitment to advancing both patient access and care a
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of John E. Bishop, Ph.D., to the leadership team as senior vice president and chief technology officer. In this role, Dr. Bishop will lead chemistry, manufacturing and control (CMC)-related functions and quality, encompassing Forma's early pipeline through commercial product. "We are fortunate to welcome John to Forma at this pivotal time in Forma's history," said Frank Lee, chief executive officer of Forma. "John's extensive expertise in small-molecule pharmaceuticals and proven track record as a leader will help to e
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today provided a review of corporate highlights from 2020 and outlined anticipated key clinical program milestones for 2021. “While 2020 was marked by tremendous challenges due to the COVID-19 pandemic, Forma made important strides due to the courage of patients and the dedication of our employees. We reported promising results our from our clinical programs including FT-4202 in sickle cell disease, olutasidenib in both AML and glioma, and FT-7051 in prostate cancer, and also raised approximately $695 mil
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that Selwyn M. Vickers, M.D., F.A.C.S., has been elected to serve on the company’s board of directors. Dr. Vickers is a world-renowned surgeon, pancreatic cancer researcher and pioneer in health disparities research. He currently serves as senior vice president of medicine and dean of the School of Medicine at The University of Alabama at Birmingham (UAB). As dean, Dr. Vickers leads the medical school’s main campus in Birmingham and the regional campuses in Montgomery, Huntsville and Tusca
15-12G - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
EFFECT - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
POS AM - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
SC 14D9/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC TO-T/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
25-NSE - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
Novo Nordisk and Forma Therapeutics, Holdings Inc. (NASDAQ:FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005393/en/ The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk's strategy t
Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia Highlighted progress across portfolio at inaugural Research and Development (R&D) Day Appointed new members of Executive Team to prepare for growth in late-stage clinical development and commercialization Cash balance of $395.9 million positions company with runway through the third quarter of 2024
Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the treatment of relapsed or refractory acute myeloid leukemiaFDA has accepted Forma's NDA for olutasidenib, with a PDUFA target action date of February 15, 2023Forma to receive an upfront payment of $2.0 million and is eligible to receive an additional $17.5 million upon the achievement of certain near-term regulatory, approval, and first commercial sale milestones, as well as potential future development and commercial milestone payments of $215.5 million and tiered royalties in the low-teens to mid-thirtiesIf approved, olutasidenib would be Ri
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, today announced that it will release second quarter 2022 financial results Friday, August 5, 2022. Forma management will host an investment community conference call at 8 a.m. Eastern Daylight Time (EDT) on August 5, 2022 to discuss these financial results and provide a business update. Investors may participate in the call by using the registration link here. Once registered, participants will receive a dial-in number as well as a PIN to enter the event. A live webcast of the conference call will
Clinical programs advancing in rare hematologic diseases and cancers May 26 R&D Day to focus on research pipeline strategy and expanded development programs Cash balance of $441.3 million positions company with runway through the third quarter of 2024 Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today reported financial results for the first quarter ended March 31, 2022. The company also highlighted recent progress and upcoming milestones for its pipeline programs. "The first quarter of 2022 was one of continued progress in enrolling ongoing tri
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release first quarter 2022 financial results Friday, May 6, 2022. Forma management will host an investment community conference call at 8 a.m. Eastern Daylight Time (EDT) on May 6, 2022 to discuss these financial results and provide a business update. Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 1879297. A live webcast of the conference call will be available in the "News & Inve
Clinical stage programs focused on rare hematologic diseases and cancers Comprehensive etavopivat Phase I SCD trial completed with results supporting tolerability and benefits in hematologic biomarkers and red blood cell health; pivotal Phase II/III trial enrolling Initial FT-7051 Phase I results in mCRPC showed tolerability/safety and signs of pharmacodynamic and clinical activity; escalating dose results expected mid-2022 Well-capitalized with nearly $500 million in cash providing runway through the third quarter of 2024 Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release fourth quarter and year-end 2021 financial results Tuesday, March 1, 2022. Forma management will host an investment community conference call at 8 a.m. Eastern Standard Time (EST), on March 1, 2022 to discuss these financial results and provide a business update. Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 3322907. A live webcast of the conference call will be available
Significant progress achieved on three clinical stage programs focused on rare hematologic diseases and cancers Etavopivat Phase 1 open label extension enrollment in sickle cell disease (SCD) complete, updated results to be presented at American Society of Hematology (ASH) Annual Meeting December 11-14 Initial Phase 1 results presented in men with metastatic castration-resistant prostate cancer (mCRPC ) showed FT-7051 well-tolerated with evidence of clinical activity Olutasidenib combination data in relapsed/refractory acute myeloid leukemia (R/R/ AML) to be presented at ASH Annual Meeting December 11-14 Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release third quarter 2021 financial results Friday, Nov. 12, 2021. Forma management will host an investment community conference call at 8 a.m. Eastern Time, on Nov. 12, 2021 to discuss these financial results and provide a business update. Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 6662686. A live webcast of the conference call will be available in the "News & Investors"